Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Overview
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Source
Originally published at www.cnbc.com.
Related Articles
- Qualcomm CEO says AI agents will replace apps — as chip giant works on 40 new AI-powered devices
- 1 Analyst Puts the Odds of a Tesla and SpaceX Merger at 80%. Here's What That Would Mean for Tesla Investors.
- Gold sell-off was a 'reset,' says Barclays — and these mining stocks could benefit from a rebound
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
